Abstract 5022
Background
Subset analysis of trials investigating taxanes in patients with mCRPC suggest an association between Grade ≥3 NP and disease outcomes. In the Phase 3 PROSELICA trial (NCT01308580), NP was more common in patients receiving cabazitaxel 25 mg/m2 (C25) vs cabazitaxel 20 mg/m2 (C20) - 73% vs 42%, respectively. Post hoc analyses of PROSELICA examined the relationship between incidence of NP, survival and response.
Methods
PROSELICA assessed the non-inferiority of C20 (n = 598) vs C25 (n = 602) in terms of overall survival (OS) in men with mCRPC. Prophylactic granulocyte colony-stimulating factor was given to patients with Grade ≥3 NP. OS and progression-free survival (PFS) were analyzed using Kaplan-Meier (KM) estimates and Cox proportional hazard models. Nominal p values were determined by log-rank tests. Prostate-specific antigen response rate (PSArr; defined as proportion of patients with a > 50 % PSA decline from baseline) was analyzed in the eligible population using KM estimates with Chi2 tests and odds ratios. OS, PFS and PSArr were correlated with Grade ≥3 NP occurrence and baseline neutrophilia (neutrophils ≥7000 G/l) by univariate analysis.
Results
In the intent-to-treat (ITT) population, development of Grade ≥3 NP was associated with better PSArr, PFS and OS (p < 0.001; Table). The positive association was observed in both treatment arms and in poor-risk patients with baseline neutrophilia.Table: 811P
| Population | Outcome | Grade ≥3 NP | No Grade ≥3 NP | Hazard ratio/Odds ratio | p value |
|---|---|---|---|---|---|
| ITT population (n = 1200) | OS, months (mo) | 15.1 | 12.4 | 0.78 | 0.0002 |
| PFS, mo | 3.7 | 2.8 | 0.79 | 0.0001 | |
| PSArr, % n = 1079 | 44.1 | 25.5 | 2.3 | <0.0001 | |
| C25 (n = 602) | OS, mo | 15.3 | 12.2 | 0.77 | 0.009 |
| PFS, mo | 3.5 | 3.5 | 0.84 | 0.07 | |
| PSArr, % n = 538 | 46.2 | 34.5 | 1.6 | 0.015 | |
| C20 (n = 598) | OS, mo | 14.6 | 12.6 | 0.78 | 0.006 |
| PFS, mo | 4.2 | 2.3 | 0.75 | 0.0008 | |
| PSArr, % n = 541 | 40.7 | 21.3 | 2.5 | <0.0001 | |
| Neutrophilia (n = 174) | OS, mo | 12.8 | 7.5 | 0.63 | 0.004 |
| PFS, mo | 4.1 | 2.1 | 0.66 | 0.008 | |
| PSArr, % n = 156 | 43.8 | 16.9 | 3.8 | 0.0002 |
Conclusions
Post hoc assessment of Grade ≥3 NP in PROSELICA was associated with improved survival and response to cabazitaxel independent of dose. These results are consistent with data obtained in the Phase 3 TAX327 (docetaxel) and TROPIC (cabazitaxel) trials. Funded by Sanofi.
Clinical trial identification
NCT01308580.
Legal entity responsible for the study
Sanofi.
Funding
Sanofi.
Editorial Acknowledgement
Editorial assistance was provided by Danielle Lindley of Meditech Media Ltd, funded by Sanofi.
Disclosure
Meisel: Advisor: Astellas, Roche, Celgene, Novartis, Vifor, Sanofi, Amgen, Merck; Expert testimony: Sanofi; Research funding: Bayer (himself), Merck (institution); Expenses: Amgen, Astellas, Sanofi, Servier, Roche, Boehringer Ingelheim; Intellectual property: Merck. R. de Wit: Consultancy, Speaker fees: Sanofi. S. Oudard: Consultancy, Advisory role, Honoraria, Expense: Sanofi, Astellas, Janssen, and Ipson; Research funding: Sanofi; Speakers bureau: Sanofi, Janssen. O. Sartor: Advisor: Bellicum Pharmaceuticals, Dendreon; Advisor, Expenses: Bayer, Johnson & Johnson, Medivation, Oncogenex, Sanofi, Tokai Pharmaceuticals, AstraZeneca, Progenics; Funding (Institute): Bayer, Johnson & Johnson, Sanofi, Dendreon, Endocyte, Innocrin Pharma, Progenics. F. Stenner-Liewen: Consultancy, Advisory role, Research, expenses: Sanofi. S. Guillonneau, A. Ozatilgan: Employee: Sanofi. M. Eisenberger: Honoraria, Consultancy, Advisory role: Sanofi, Pfizer, Astellas; Research: Sanofi; Expenses: Sanofi, Pfizer. J.S. de Bono: Honoraria: Sanofi; Advisor: Sanofi, AstraZeneca, GSK, Genentech, Roche, Merck; Speakers bureau: AstraZeneca/MedImmune; Research funding (Institute): AstraZeneca/MedImmune, GSK, Sanofi, Merck Sharp & Dohme, Genmab, Genentech; Patent on abiraterone acetate with prednisone.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract